Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins

Drug Delivery

Ji-Xin Zhong¹  Bo-Xu Ren²  Ying Xiang³  Jun-Ting Cheng³  Ying-Ying Wang³  Zhao-Wu Ma³  Hong-Wu Xin³  Xiao-Qin Liu⁴  Zi-Jun Wu⁴  Xian-Wang Wang⁵  Xiao-Chun Peng⁶  Yan-Ning Lyu⁷  Jia-Fu Ji⁸  Hong-Yi Xin⁹ 

[1] Cardiovascular Research Institute, Case Western Reserve University, Cleveland, OH, USA;Faculty of Medicine, The Second School of Clinical Medicine, Yangtze University, Nanhuan, Jingzhou, Hubei, China;Department of Nursing and Medical Imaging Technology, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, The Second School of Clinical Medicine, Yangtze University, Nanhuan, Jingzhou, Hubei, China;Laboratory of Oncology, Faculty of Medicine, Center for Molecular Medicine, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, The Second School of Clinical Medicine, Yangtze University, Nanhuan, Jingzhou, Hubei, China;Laboratory of Oncology, Faculty of Medicine, Center for Molecular Medicine, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Department of Nursing and Medical Imaging Technology, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, The Second School of Clinical Medicine, Yangtze University, Nanhuan, Jingzhou, Hubei, China;Laboratory of Oncology, Faculty of Medicine, Center for Molecular Medicine, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, Department of Laboratory Medicine, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, Chin;Faculty of Medicine, The Second School of Clinical Medicine, Yangtze University, Nanhuan, Jingzhou, Hubei, China;Laboratory of Oncology, Faculty of Medicine, Center for Molecular Medicine, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Faculty of Medicine, Department of Pathophysiology, School of Basic Medicine, Yangtze University, Jingzhou, Hubei, China;Institute for Infectious Diseases and Endemic Diseases Prevention and Control, Beijing Center for Diseases Prevention and Control, Beijing, China;Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Haidian, Beijing, China;Star Array Pte Ltd, JTC Medtech Hub, Singapore, Singapore;

关键词: Oncolytic virotherapy;    herpes simplex virus;    envelope glycoprotein;    tumor targeting;    immune escape;    neutralization antibody;   

DOI  :  10.1080/10717544.2018.1534895

来源: publisher

【 摘 要 】

Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and some side effects. To overcome such challenges, here we review the genetic engineering of the envelope glycoproteins for oHSVs to target tumors specifically, and at the same time we summarize the many neutralization antibodies against the envelope glycoproteins and align the neutralization epitopes with functional domains of the respective glycoproteins for future identification of new functions of the glycoproteins and future engineering of the epitopes to escape from host neutralization.

【 授权许可】

CC BY